HyClone units to keep Utah and Colorado HQs says GE Healthcare

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Ge healthcare, Biotechnology, Dna, Life

HyClone units to keep Utah and Colorado HQs says GE
HyClone units to keep Utah and Colorado HQs says GE
GE Healthcare has confirmed it will continue to run the HyClone units it is buying from Thermo Fisher Scientific from their existing US bases.

The firm announced it would pay Thermo Fisher Scientific $1.06bn (€780m) for its gene modulation and magnetic beads units on Monday in a deal prompted by the latter’s efforts to comply with EU competition​ laws ahead of its purchase of Life Technologies​.

The Thermo units GE is buying are based in the US from where they will continue to operate according to Nigel Darby, Vice President BioProcess, GE Healthcare Life Sciences. 

He told BioPharma-Reporter.com that: “It is intended that the businesses will continue to operate from their respective facilities. The cell culture media and sera business will continue to be run from Utah, and the gene modulation business will continue to be run from Colorado.

In addition to the two US sites, the divested Thermo units have facilities in Singapore, Australia, New Zealand and Belgium, which also look likely to be kept on.

Darby said: “HyClone’s state-of-the-art manufacturing facilities will strengthen and expand GE’s supply chain capabilities in Asia, the Americas and Europe​” adding that “The businesses will become part of GE Healthcare’s Life Sciences, which is headquartered in the UK.  As the deal hasn’t closed, it is too early to talk in more detail​.” 

The Thermo businesses employ 625 people and while it looks like some staff will be joining GE, Darby did not say how many when we asked.

This proposed acquisition is about growth, encompassing business lines that truly add new competences and new technologies. GE Healthcare highly values the employees who would be joining GE as part of this acquisition. 

“The expertise and knowledge of Thermo Fisher’s employees will be critical in the continuing growth of the GE Healthcare Life Sciences business​.”

Technology expansion

If the deal HyClone deal is completed GE stands to further expand its biomanufacturing offering like it did when it bought Wave Biotech​ and Xcellerex​, which was also a driver according to Darby.

The addition of HyClone cell culture media and sera products to GE Healthcare’s business will allow us to offer customers a substantially wider range of fully integrated products and services for biopharmaceutical manufacturing and biomedical research.​ 

The [HyClone] RNAi gene modulation technologies have a strong strategic fit with GE’s established technologies for drug discovery research​,” he said adding that “The Sera-Mag magnetic bead separation business is complementary to GE’s existing capabilities in protein analysis and medical diagnostics.”

Related news

Show more

Related products

show more

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...


Inline diafiltration enables continuous processing

Pall Life Sciences | 13-Feb-2018 | Application Note

The Cadence inline diafiltration (ILDF) device is designed for continuous processing, in-process buffer exchange or contaminant removal in various processes...

Related suppliers